Skip Navigation

Nucleic Acids Symposium Series 2002 2(1):115-116; doi:10.1093/nass/2.1.115
© 2002 by Oxford University Press
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Iyo, M.
Right arrow Articles by Taira, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iyo, M.
Right arrow Articles by Taira, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Construction of an allosteric trans-maxizyme targeting for two distinct oncogenes

Mayu Iyo1, Hiroaki Kawasaki1,2 and Kazunari Taira1,2

1 Department of Chemistry and Biotechnology, School of Engineering, The University of Tokyo, 7-3-1 Hongo, Tokyo 113-8656, Japan, 2 Gene Function Research Laboratory, National Institute of Advanced Industrial Science and Technology (AIST), Central 4, 1-1-1 Higashi, Tsukuba Science City 305-8562, Japan

A maxizyme is dimmer of minimized ribozymes (minizymes) and can specifically cleave two target sites. The maxizyme also can allosterically cleave the target RNA only when it recognizes two target sites. In this study, for a cancer gene therapy, we focused two distinct oncogenes, cyclinD1 and hst-1, which are overexpressed in breast cancer cells. If we use conventional ribozymes for suppression of expression of those genes, these ribozymes affect not only these mRNAs in cancer cells but also those in normal cells because those genes are necessary for a growth factor-dependent signal transduction and a cell cycle in normal cells. To overcome this problem, we tried to design the trans-maxizyme that can cleave these mRNAs only in the breast cancer cells.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.